Scottish Medicines Consortium Approves Fycompa® (Perampanel) - Once Daily Anti-Epileptic Treatment

Scottish Medicines Consortium Approves Fycompa® (Perampanel) - Once Daily Anti-Epileptic Treatment PR Newswire HATFIELD, England, December 10, 2012 HATFIELD, England, December 10, 2012 /PRNewswire/ -- Fycompa (perampanel), a treatment for partial epilepsy, is now approved for use in Scotland after a decision by The [1]Scottish Medicines Consortium (SMC). It is approved for use as a second-line adjunctive treatment in patients with [1]refractory partial-onset epilepsy. [2]Almost 54,000 people in Scotland have epilepsy, one of the most common neurological diseases. The number of people affected by the condition has been on the increase in Scotland, which saw nearly a 40% increase in six years [2]signifying a critical need for effective treatments for managing the condition. The SMC approval for perampanel is the first health technology appraisal (HTA) globally. "This approval from the SMC is a positive step in the management of people with epilepsy in Scotland. Uncontrolled seizures have a severe impact on everyday function and quality of life and so we look forward to the possibility of being able to offer our epilepsy patients a new treatment option," comments Professor Martin Brodie, Professor of Medicine and Clinical Pharmacology at the University of Glasgow and Director of the Epilepsy Unit at the city's Western Infirmary. The data supports the use of perampanel as a new therapeutic option for this hard-to-treat patient population.